BlackRock Portfolio holdings
BlackRock, Inc., founded in 1988 by Larry Fink and a group of partners, is the world’s largest asset management firm, headquartered in New York City. Initially starting as a risk management and fixed-income institutional asset manager, it has grown to manage over $10 trillion in assets through a combination of organic growth and strategic acquisitions, such as its 2009 purchase of Barclays Global Investors. BlackRock is known for its extensive range of investment products, including mutual funds, ETFs (notably under the iShares brand), and alternative investments, serving clients ranging from individuals to governments.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Moderna
MRNA
|
+$2.76B |
| 2 |
Analog Devices
ADI
|
+$2.38B |
| 3 |
Amazon
AMZN
|
+$2.01B |
| 4 |
Tesla
TSLA
|
+$1.68B |
| 5 |
Snowflake
SNOW
|
+$1.58B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$3.21B |
| 2 |
MXIM
Maxim Integrated Products
MXIM
|
+$2.54B |
| 3 |
Vanguard Short-Term Corporate Bond ETF
VCSH
|
+$1.28B |
| 4 |
Alibaba
BABA
|
+$1.25B |
| 5 |
WORK
Slack Technologies, Inc.
WORK
|
+$1.15B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 23.26% |
| 2 | Healthcare | 13.81% |
| 3 | Financials | 13.25% |
| 4 | Consumer Discretionary | 11.13% |
| 5 | Communication Services | 8.92% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
NAGE
3276
Niagen Bioscience
NAGE
$241M
| $19.7M | ﹤0.01% |
3,143,681
+25,074
| +0.8% | +$207K |
|
|
BFX
3277
DELISTED
BowFlex Inc.
BFX
| $19.6M | ﹤0.01% |
2,108,627
-35,693
| -2% | -$458K |
|
|
NYXH
3278
Nyxoah
NYXH
$158M
| $19.6M | ﹤0.01% |
+670,577
| New | +$21.2M |
|
3279
AbCellera Biologics
ABCL
$3.36B
| $19.6M | ﹤0.01% |
976,587
+79,400
| +9% | +$1.4M |
|
3280
Angi Inc
ANGI
$196M
| $19.5M | ﹤0.01% |
158,232
-6,136
| -4% | -$705K |
|
3281
Lifecore Biomedical
LFCR
$181M
| $19.5M | ﹤0.01% |
2,112,182
-93,227
| -4% | -$1.01M |
|
|
FORG
3282
DELISTED
ForgeRock, Inc.
FORG
| $19.5M | ﹤0.01% |
+500,000
| New | +$21M |
|
|
SYRS
3283
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| $19.5M | ﹤0.01% |
435,367
-10,969
| -2% | -$535K |
|
3284
CuriosityStream
CURI
$237M
| $19.4M | ﹤0.01% |
1,841,907
+15,445
| +0.8% | +$182K |
|
|
NOTV
3285
DELISTED
Inotiv
NOTV
| $19.4M | ﹤0.01% |
663,691
+27,944
| +4% | +$813K |
|
3286
Paymentus
PAY
$5.31B
| $19.3M | ﹤0.01% |
785,250
-31,011
| -4% | -$878K |
|
|
ISZE
3287
DELISTED
iShares MSCI Intl Size Factor ETF
ISZE
| $19.3M | ﹤0.01% |
620,521
+245,817
| +66% | +$7.84M |
|
3288
Neurogene
NGNE
$740M
| $19.3M | ﹤0.01% |
133,464
+1,526
| +1% | +$234K |
|
|
ATHX
3289
DELISTED
Athersys, Inc. Common Stock
ATHX
| $19.3M | ﹤0.01% |
580,024
+8,939
| +2% | +$340K |
|
3290
Design Therapeutics
DSGN
$901M
| $19.3M | ﹤0.01% |
1,312,664
-90,678
| -6% | -$1.51M |
|
|
NEUE
3291
DELISTED
NeueHealth
NEUE
| $19.3M | ﹤0.01% |
+29,505
| New | +$26M |
|
3292
Aligos Therapeutics
ALGS
$43.7M
| $19.2M | ﹤0.01% |
49,582
+6,220
| +14% | +$2.46M |
|
3293
Amalgamated Financial
AMAL
$1.53B
| $19.2M | ﹤0.01% |
1,213,726
-46,742
| -4% | -$715K |
|
3294
Harvard Bioscience
HBIO
$28.1M
| $19.1M | ﹤0.01% |
273,747
+605
| +0.2% | +$48.1K |
|
3295
Vanguard Real Estate ETF
VNQ
$39.1B
| $19.1M | ﹤0.01% |
187,579
-237,266
| -56% | -$25.2M |
|
3296
iShares MSCI France ETF
EWQ
$332M
| $19.1M | ﹤0.01% |
512,270
-904,885
| -64% | -$34.6M |
|
|
INDT
3297
DELISTED
INDUS Realty Trust, Inc. (MD) Common Stock
INDT
| $19M | ﹤0.01% |
271,448
-1,890
| -0.7% | -$129K |
|
|
CBAY
3298
DELISTED
Cymabay Therapeutics
CBAY
| $19M | ﹤0.01% |
5,205,478
-226,192
| -4% | -$891K |
|
|
LONA
3299
LeonaBio Inc
LONA
$73.9M
| $18.8M | ﹤0.01% |
200,890
+1,585
| +0.8% | +$161K |
|
|
JNCE
3300
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
| $18.8M | ﹤0.01% |
2,534,851
+77,752
| +3% | +$482K |
|
Similar funds
BlackRock's Q3 2021 Portfolio in Review
As of Q3 2021, BlackRock held 5,803 positions worth $3.57T, down 0.58% from $3.59T the previous quarter. Its ten largest holdings account for 19% of the portfolio.
BlackRock's Q3 2021 filing shows 283 new, 2,199 increased, 2,669 reduced and 164 closed positions. Its largest new stake was GXO Logistics: 8,566,775 shares worth $672M. The largest sale was Alexion Pharmaceuticals, an estimated $3.21B.
By sector, the portfolio is most concentrated in Technology at 23% of assets, up from 23% a quarter earlier, followed by Healthcare and Financials.
- BlackRock's largest Q3 2021 buy was GXO Logistics: 8,566,775 shares worth $672M.
- BlackRock added most to Moderna in Q3 2021, an estimated $2.76B increase.
- BlackRock's biggest Q3 2021 reduction was Vanguard Short-Term Corporate Bond ETF, cutting an estimated $1.28B.
- BlackRock fully exited Alexion Pharmaceuticals in Q3 2021, selling an estimated $3.21B.
- BlackRock's ten largest holdings make up 19% of its $3.57T portfolio in Q3 2021.
- BlackRock opened 283 new positions and closed 164 in Q3 2021.
- BlackRock's portfolio value fell 0.58% quarter-over-quarter to $3.57T.
Based on BlackRock's 13F filing for Q3 2021, filed 9 Nov 2021.